%A LI Xia-yi, ZHENG Lei-zhen %T Application of programmed cell death protein 1/programmed death-ligand 1 blockade in advanced gastric cancer treatment %0 Journal Article %D 2018 %J Journal of Shanghai Jiao Tong University (Medical Science) %R 10.3969/j.issn.1674-8115.2018.10.022 %P 1259- %V 38 %N 10 %U {https://xuebao.shsmu.edu.cn/CN/abstract/article_12061.shtml} %8 2018-10-28 %X In the tumor microenvironment, the interaction of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) can promote the immune escape of tumor cells. The application of PD-1/PD-L1 blockade can restore host immune function to efficiently identify and kill tumor cells. In recent years, PD-1/PD-L1 blockade has shown remarkable clinical effects in a variety of tumors and U.S. Food and Drug Administration has approved nivolumab and pembrolizumab for the treatment of unresectable/metastatic melanoma, non-small cell lung cancer and etc. Hence, a growing number of clinical trials on PD-1/PD-L1 blockade for advanced gastric cancer have been carried out, and the overall survival and objective response rate of most trials are promising. This paper reviewed PD-1/PD-L1 signaling pathway, the relationship between the of PD-L1 and the classification and prognosis of gastric cancer, and the clinical results of PD-1/PD-L1 blockade in advanced gastric cancer.